Chronic Hepatitis B
Conditions
Interventions
Group A:Entecavir 0.5mg orally taken once daily for 12 months, and Lingmao Granules 1 one package orally taken twice daily for 12 months (six-month follow-up)
Group B:Entecavir 0.5mg orally taken once daily for 12 months, and Lingmao Granules 2 one package orally taken twice daily for 12 months (six-month follow-up)
Group C:Lingmao Granules 1 one package orally taken twice daily for 12 months (six-month follow-up)
Group D:Lingmao Granules 2 one package orally taken twice daily for 12 months (six-month follow-up)
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Male and female aged 18 to 65 years old; 2. Diagnosed as Chronic Hepatitis B, have not been treated with anti-viral treatment in western medicine; 3. 1*ULN<=ALT<2*ULN; 4. Patients who have not been treated with Chinese and western medicine to reduce transaminase in the latest month; 5. Able and willing to provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Chronic Severe Hepatitis and Liver Cirrhosis; 2. Hepatitis infected with other type of hepatovirus; 3. Patients who have serious primary disease in heart, kidney, lung, endocrine system, blood, metabolism, or gastrointestinal tract; 4. Patients with mental disease; 5. Pregnant or lactating women; 6. allergic to drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA;Liver Biopsy;Liver Function index;Liver morphological change;HBV antigen and antibody complete set test;Quality of life scale for Chronic Hepatitis; | — |
Countries
China
Contacts
Public ContactYueqiu Gao
Outcome results
None listed